As previously announced, the Düsseldorf company is thereby discontinuing operations which are not part of the core business of pharmaceutics and life science.
“The consumer healthcare business did not fit in with our strategy of focussing on the fields of pharmaceutics and life science. In addition, because of the lack of synergies with the core business, our return requirements for the consumer healthcare business were not fulfilled,” says Gerresheimer CEO Dr. Axel Herberg.
The consumer healthcare business, which comprises the production of toothbrushes and other interdental articles and most recently achieved annual sales of €24m, was part of the Wilden Group, which was acquired in January 2007. The purchaser is the Krallmann Group. Through the acquisition, Krallmann intends to expand its own plastic processing division and to continue the business under the traditional “Interbros” trademark. The transaction takes place with effect on 1 June 2008. The contractual parties have agreed to keep further details confidential.
Early this year, Gerresheimer already discontinued the marginal business of aluminium packaging with sales of €3.3m.
Gerresheimer employs more than 10,800 people in 41 locations in Europe, America and Asia. In the financial year 2007, worldwide sales totalled €957.7m. The product portfolio ranges from pharmaceutical vials made of glass and plastic through to complex drug-delivery systems for the pharma & life science industry. These include sterile syringes, inhalers and other system-based approaches for safe dosage and application of medications. The Group enjoys a leading position in markets which are characterised by high technical and regulatory barriers.
Director Corporate PR & Marketing
Telephone +49 211 6181-250
Telefax +49 211 6181-241